Literature DB >> 20106982

CDKN1C negatively regulates RNA polymerase II C-terminal domain phosphorylation in an E2F1-dependent manner.

Yihong Ma1, Lu Chen, Gabriela M Wright, Smitha R Pillai, Srikumar P Chellappan, W Douglas Cress.   

Abstract

CDKN1C is a cyclin-dependent kinase inhibitor and is a candidate tumor suppressor gene. We previously found that the CDKN1C protein represses E2F1-driven transcription in an apparent negative feedback loop. Herein, we explore the mechanism by which CDKN1C represses transcription. We find that adenoviral-mediated overexpression of CDKN1C leads to a dramatic reduction in phosphorylation of the RNA polymerase II (pol II) C-terminal domain (CTD). RNA interference studies demonstrate that this activity is not an artifact of CDKN1C overexpression, because endogenous CDKN1C mediates an inhibition of RNA pol II CTD phosphorylation in HeLa cells upon treatment with dexamethasone. Surprisingly, we find that CDKN1C-mediated repression of RNA pol II phosphorylation is E2F1-dependent, suggesting that E2F1 may direct CDKN1C to chromatin. Chromatin immunoprecipitation assays demonstrate that CDKN1C is associated with E2F1-regulated promoters in vivo and that this association can dramatically reduce the level of RNA pol II CTD phosphorylation at both Ser-2 and Ser-5 of the C-terminal domain repeat. In addition, we show that CDKN1C interacts with both CDK7 and CDK9 (putative RNA pol II CTD kinases) and that CDKN1C blocks their ability to phosphorylate a glutathione S-transferase-CTD fusion protein in vitro. E2F1 and CDKN1C are found to form stable complexes both in vivo and in vitro. Molecular studies demonstrate that the E2F1-CDKN1C interaction is mediated by two E2F domains. A central E2F1 domain interacts directly with CDKN1C, whereas a C-terminal E2F1 domain interacts with CDKN1C via interaction with Rb. The results presented in this report highlight a novel mechanism of tumor suppression by CDKN1C.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20106982      PMCID: PMC2843230          DOI: 10.1074/jbc.M109.091496

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  62 in total

1.  p19ARF targets certain E2F species for degradation.

Authors:  F Martelli; T Hamilton; D P Silver; N E Sharpless; N Bardeesy; M Rokas; R A DePinho; D M Livingston; S R Grossman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

Review 2.  Histone deacetylases, transcriptional control, and cancer.

Authors:  W D Cress; E Seto
Journal:  J Cell Physiol       Date:  2000-07       Impact factor: 6.384

3.  Physical interaction between CDK9 and B-Myb results in suppression of B-Myb gene autoregulation.

Authors:  G De Falco; L Bagella; P P Claudio; A De Luca; Y Fu; B Calabretta; A Sala; A Giordano
Journal:  Oncogene       Date:  2000-01-20       Impact factor: 9.867

4.  The paradox of E2F1: oncogene and tumor suppressor gene.

Authors:  D G Johnson
Journal:  Mol Carcinog       Date:  2000-03       Impact factor: 4.784

5.  From androgen receptor to the general transcription factor TFIIH. Identification of cdk activating kinase (CAK) as an androgen receptor NH(2)-terminal associated coactivator.

Authors:  D K Lee; H O Duan; C Chang
Journal:  J Biol Chem       Date:  2000-03-31       Impact factor: 5.157

6.  Human ARF binds E2F1 and inhibits its transcriptional activity.

Authors:  B Eymin; L Karayan; P Séité; C Brambilla; E Brambilla; C J Larsen; S Gazzéri
Journal:  Oncogene       Date:  2001-03-01       Impact factor: 9.867

7.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

Review 8.  The Rb/E2F pathway and cancer.

Authors:  J R Nevins
Journal:  Hum Mol Genet       Date:  2001-04       Impact factor: 6.150

9.  c-Myc mediates activation of the cad promoter via a post-RNA polymerase II recruitment mechanism.

Authors:  S R Eberhardy; P J Farnham
Journal:  J Biol Chem       Date:  2001-10-22       Impact factor: 5.157

Review 10.  Emerging roles of E2Fs in cancer: an exit from cell cycle control.

Authors:  Hui-Zi Chen; Shih-Yin Tsai; Gustavo Leone
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

View more
  11 in total

1.  JAZ mediates G1 cell cycle arrest by interacting with and inhibiting E2F1.

Authors:  Mingli Yang; Song Wu; Jinghua Jia; W Stratford May
Journal:  Cell Cycle       Date:  2011-07-15       Impact factor: 4.534

Review 2.  Specific changes in the expression of imprinted genes in prostate cancer--implications for cancer progression and epigenetic regulation.

Authors:  Teodora Ribarska; Klaus-Marius Bastian; Annemarie Koch; Wolfgang A Schulz
Journal:  Asian J Androl       Date:  2012-02-27       Impact factor: 3.285

3.  CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21.

Authors:  Huabiao Chen; Chun Li; Jinghe Huang; Thai Cung; Katherine Seiss; Jill Beamon; Mary F Carrington; Lindsay C Porter; Patrick S Burke; Yue Yang; Bethany J Ryan; Ruiwu Liu; Robert H Weiss; Florencia Pereyra; William D Cress; Abraham L Brass; Eric S Rosenberg; Bruce D Walker; Xu G Yu; Mathias Lichterfeld
Journal:  J Clin Invest       Date:  2011-03-14       Impact factor: 14.808

4.  Sexually dimorphic actions of glucocorticoids provide a link to inflammatory diseases with gender differences in prevalence.

Authors:  Danielle Duma; Jennifer B Collins; Jeff W Chou; John A Cidlowski
Journal:  Sci Signal       Date:  2010-10-12       Impact factor: 8.192

5.  Tripartite motif containing 28 (Trim28) can regulate cell proliferation by bridging HDAC1/E2F interactions.

Authors:  Lu Chen; Dung-Tsa Chen; Courtney Kurtyka; Bhupendra Rawal; William J Fulp; Eric B Haura; W Douglas Cress
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

6.  Trim28 contributes to EMT via regulation of E-cadherin and N-cadherin in lung cancer cell lines.

Authors:  Lu Chen; Teresita Muñoz-Antonia; W Douglas Cress
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

7.  Splicing inhibition decreases phosphorylation level of Ser2 in Pol II CTD.

Authors:  Mitsunori Koga; Megumi Hayashi; Daisuke Kaida
Journal:  Nucleic Acids Res       Date:  2015-07-21       Impact factor: 16.971

8.  Depletion of ZBTB38 potentiates the effects of DNA demethylating agents in cancer cells via CDKN1C mRNA up-regulation.

Authors:  Claire Marchal; Maud de Dieuleveult; Claude Saint-Ruf; Nadège Guinot; Laure Ferry; Sara T Olalla Saad; Mariana Lazarini; Pierre-Antoine Defossez; Benoit Miotto
Journal:  Oncogenesis       Date:  2018-10-11       Impact factor: 7.485

9.  E2F inhibition synergizes with paclitaxel in lung cancer cell lines.

Authors:  Courtney A Kurtyka; Lu Chen; W Douglas Cress
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

10.  Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.

Authors:  Abderrahim El Guerrab; Mahchid Bamdad; Fabrice Kwiatkowski; Yves-Jean Bignon; Frédérique Penault-Llorca; Corinne Aubel
Journal:  Oncotarget       Date:  2016-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.